# Generate:Biomedicines: Now we can\.

> Generate Biomedicines is a new kind of therapeutics company—existing at the intersection of biology, machine learning, and biological engineering\.

Generated by Yoast SEO v28.7, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [Pipeline](https://generatebiomedicines.com/pipeline/)
- [Chroma](https://generatebiomedicines.com/chroma/)
- [Home](https://generatebiomedicines.com/)
- [Careers](https://generatebiomedicines.com/careers/)
- [Biomedicines](https://generatebiomedicines.com/biomedicines/)

## Team Members
- [Jason Silvers](https://generatebiomedicines.com/team-member/jason-silvers/)
- [Rupert Vessey](https://generatebiomedicines.com/team-member/rupert-vessey/)
- [Nancy Simonian](https://generatebiomedicines.com/team-member/nancy-simonian/)
- [Paul Parker](https://generatebiomedicines.com/team-member/paul-parker/)
- [Jane Mendillo](https://generatebiomedicines.com/team-member/jane-mendillo/)

## Blog Posts
- [Designing Beyond Viral Evolution: Peer\-Reviewed First\-in\-Human Results for GB\-0669](https://generatebiomedicines.com/blog-posts/designing-beyond-viral-evolution-peer-reviewed-first-in-human-results-for-gb-0669/)
- [Generate:Chroma: A generative model for protein design](https://generatebiomedicines.com/blog-posts/generatechroma-a-generative-model-for-protein-design/)
- [Engineering CAR T\-Cells to Function Where Others Fail](https://generatebiomedicines.com/blog-posts/engineering-car-t-cells-to-function-where-others-fail/)
- [Designing Beyond Tolerability Limits: Advancing GB\-4362 Into Clinical Development ](https://generatebiomedicines.com/blog-posts/designing-beyond-tolerability-limits-advancing-gb-4362-into-clinical-development/)
- [Introducing Generative Biology, Part I: Extracting the Hidden Principles of Biology with Machine Learning](https://generatebiomedicines.com/blog-posts/introducing-generative-biology-part-i/)

## News Releases
- [Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases](https://generatebiomedicines.com/news-releases/generate-biomedicines-and-zealand-pharma-enter-collaboration-and-license-agreement-to-develop-protein-therapeutics-engineered-with-ai-for-metabolic-diseases/)
- [Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer](https://generatebiomedicines.com/news-releases/roswell-park-generate-biomedicines-launch-exclusive-clinical-trial-of-armored-car-t-therapy-for-ovarian-cancer/)
- [Generate Biomedicines Inc\. to Participate in September Investor Conferences ](https://generatebiomedicines.com/news-releases/generate-biomedicines-inc-to-participate-in-september-investor-conferences/)
- [Generate Biomedicines Inc\. Reports Second Quarter 2026 Financial Results and Provides Business Update](https://generatebiomedicines.com/news-releases/generate-biomedicines-inc-reports-second-quarter-2026-financial-results-and-provides-business-update/)
- [Generate:Biomedicines Announces Multi\-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI](https://generatebiomedicines.com/news-releases/generatebiomedicines-announces-multi-target-collaboration-with-novartis/)

## Media Highlights
- [Zealand Pharma CEO hails AI protein deal with Generate Biomedicines](https://generatebiomedicines.com/media-highlights/zealand-pharma-ceo-hails-ai-protein-deal-with-generate-biomedicines/)
- [Zealand Pharma Makes Deal With Generate Worth Up to $1\.2 Billion](https://generatebiomedicines.com/media-highlights/zealand-pharma-makes-deal-with-generate-worth-up-to-1-2-billion/)
- [Next in Medicine](https://generatebiomedicines.com/media-highlights/next-in-medicine/)
- [Best Workplaces for Innovators 2026: Biotech, healthcare, and life sciences category winners](https://generatebiomedicines.com/media-highlights/best-workplaces-for-innovators-2026-biotech-healthcare-and-life-sciences-category-winners/)
- [Best Workplaces for Innovators 2026: Technology and science category winners](https://generatebiomedicines.com/media-highlights/best-workplaces-for-innovators-2026-technology-and-science-category-winners/)

## Publications
- [GB\-0895 Asthma Phase 1 study ERS Barcelona 2026 Final](https://generatebiomedicines.com/publications/gb-0895-asthma-phase-1-study-ers-barcelona-2026-final/)
- [GB\-0895 COPD Phase 1 study ERS Barcelona 2026 Final](https://generatebiomedicines.com/publications/gb-0895-copd-phase-1-study-ers-barcelona-2026-final/)
- [GB\-0895 SOLAIRIA\-1 \& SOLAIRIA\-2 ERS Barcelona 2026 Final](https://generatebiomedicines.com/publications/gb-0895-solairia-1-solairia-2-ers-barcelona-2026-final/)
- [Randomized, Double\-Blind, Placebo\-Controlled First\-in\-Human Trial of a First\-in\-Class AI\-Designed Monoclonal Antibody \(GB\-0669\) Against the Conserved SARS\-CoV‑2 Spike S2 Stem Helix](https://generatebiomedicines.com/publications/randomized-double-blind-placebo-controlled-first-in-human-trial-of-a-first-in-class-ai-designed-monoclonal-antibody-gb-0669-against-the-conserved-sars-cov-2-spike-s2-stem-helix/)
- [Protein re\-surfacing of E\. coli L\-Asparaginase to evade pre\-existing anti\-drug antibodies and hypersensitivity responses](https://generatebiomedicines.com/publications/protein-re-surfacing-of-e-coli-l-asparaginase-to-evade-pre-existing-anti-drug-antibodies-and-hypersensitivity-responses-2/)

## Optional
- [Sitemap index](https://generatebiomedicines.com/sitemap_index.xml)